Journal of Clinical Densitometry
Volume 11, Issue 4 , Pages 478-484 , October 2008

A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis

  • E. Michael Lewiecki, MD, FACP, FACE

      Affiliations

    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA.

Received 4 June 2008 ,Revised 15 July 2008 ,Accepted 16 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Grant or research support: Merck, Eli Lilly, Novartis, sanofi–aventis, Amgen, Pfizer, Wyeth, Roche, GSK, Procter & Gamble; scientific advisory board or speakers' bureau: Merck, Eli Lilly, Novartis, sanofi–aventis, Amgen, Pfizer, Wyeth, Roche, GSK, Procter & Gamble, Upsher-Smith.

PII: S1094-6950(08)00211-4

doi: 10.1016/j.jocd.2008.07.003

Journal of Clinical Densitometry
Volume 11, Issue 4 , Pages 478-484 , October 2008

Article Tools

* Image Usage & Resolution